{"id":16,"date":"2024-02-09T11:01:11","date_gmt":"2024-02-09T02:01:11","guid":{"rendered":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/?page_id=16"},"modified":"2026-02-01T12:36:35","modified_gmt":"2026-02-01T03:36:35","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/publications\/","title":{"rendered":"\u7814\u7a76\u696d\u7e3e"},"content":{"rendered":"\n

\u7814\u7a76\u696d\u7e3e<\/h2>\n\n\n\n

\u5b66\u8853\u8ad6\u6587<\/h3>\n\n\n\n
    \n
  1. Miyauchi Y, Sadato Y, Sawai M, Takechi S, Hiratsuka M, Mackenzie PI, Ishii Y. UDP-glucuronosyltransferase 1A9 function is mediated by the two C-terminal lysine residues and proper mobility\/flexibility of the cytoplasmic tail. Biochem. Biophys. Res. Commun.<\/strong>, 2025 794:153004. doi: 10.1016\/j.bbrc.2025.153004. Online ahead of print. PMID: 41317709<\/li>\n\n\n\n
  2. Ohmori Y, Hishinuma E, Suzuki Y, Ueda A, Kijogi C, Nakayoshi T, Oda A, Saito S, Tadaka S, Kinoshita K, Sato Y, Hiratsuka , Comprehensive functional characterization of rare and known CYP2E1 allelic variants identified in a Japanese population. Biochem. Pharmacol.<\/strong>, (2025) 242(Pt 4):117396. doi: 10.1016\/j.bcp.2025.117396.<\/li>\n\n\n\n
  3. Saleous R, Hishinuma E, Al-Mahayri ZN, Ueda A, Suzuki Y, Ghattas MA, Mahgoub RE, Hiratsuka M, Ali BR. Evaluation of the functional impact of rare CYP2C19 missense variants identified in understudied Populations: An Integrated in silico and in vitro analysis. Biochem. Pharmacol.<\/strong>, (2025) 242(Pt 3):117350. doi: 10.1016\/j.bcp.2025.117350.<\/li>\n\n\n\n
  4. Obara T, Ishikuro M, Noda A, Murakami K, Orui M, Shinoda G, Ueno F, Matsuzaki F, Onuma T, Matsubara H, Metoki H, Kikuya M, Hatanaka R, Chiba I, Nakaya K, Kogure M, Nakaya N, Sugawara J, Kure S, Kobayashi M, Kobayashi T, Suzuki Y, Kawame H, Sakurai-Yageta M, Nagase S, Nakamura N, Nakamura T, Mizuno S, Nagaie S, Ogishima S, Narita A, Tamiya G, Koreeda S, Nagami F, Tamahara T, Goto M, Otsuki A, Taira M, Hidaka T, Kawashima J, Kodama EN, Uruno A, Hamanaka Y, Tomita H, Hashizume H, Noguchi K, Katsuoka F, Koshiba S, Kumada K, Nobukuni T, Ohneda K, Mugikura S, Shimizu R, Kambe M, Saito Y, Kobayashi T, Izumi Y, Kinoshita K, Fuse N, Yaegashi N, Hozawa A, Yamamoto M, Kuriyama S; Tohoku Medical Megabank Project Study Group. Cohort Profile Update: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study) 2023 update. Int. J. Epidemiol.<\/strong>, 54:dyaf148 (2025)<\/li>\n\n\n\n
  5. Miyauchi Y, Koba H, Sawai M, Kansui H, Takechi S, Hishinuma E, Matsukawa N, Hiratsuka M, Mackenzie PI, Ishii Y. Disulfide bond-mediated stabilization of the oligomers of UDP-glucuronosyltransferase 2B7. J. Biol. Chem.<\/strong>, 301(9):110502. doi: 10.1016\/j.jbc.2025.110502. (2025)<\/li>\n\n\n\n
  6. Shimizu M, Hishinuma E, Igarashi R, Saito S, Makiguchi M, Hiratsuka M, Yamazaki H. In silico binary classification of catalytic function (unaffected or impaired) of flavin-containing monooxygenase 3 (FMO3) variants and in vitro validation using new variants found in a Japanese genome resource database. Biol. Pharm. Bull.<\/strong>, 48:1062-1069 (2025)<\/li>\n\n\n\n
  7. Kodate S, Sato M, Hishinuma E, Kojima K, Motoike IN; ToMMo Study Group; Koshiba S, Yamamoto M, Yamada KD, Kinoshita K. Simulating metabolic pathways to enhance interpretations of metabolome genome-wide association studies. Sci. Rep.<\/strong>, 15: 17035 (2025)<\/li>\n\n\n\n
  8. Minn AKK, Matsuzaki M, Narita A, Funayama T, Kotsar Y, Makino S, Takayama J; Tohoku Medical Megabank Project Study Group; Kuriyama S, Tamiya G. Profiling of runs of homozygosity from whole-genome sequence data in Japanese biobank. J. Hum. Genet.<\/strong>, 70:287-296 (2025)<\/li>\n\n\n\n
  9. Ichinohe R, Segawa R, Nakajo T, Hiratsuka M, Yoshii T, Pirabul K, Pan ZZ, Nishihara H, Hirasawa N. Carbon-based particles inhibit antigen penetration into the skin by adsorbing the antigen. Exp. Dermatol.<\/strong>, 34:e70061 (2025)<\/li>\n\n\n\n
  10. Takase M, Nakaya N, Nakamura T, Kogure M, Hatanaka R, Nakaya K, Chiba I, Tokioka S, Kanno I, Nochioka K, Tsuchiya N, Hirata T, Narita A, Obara T, Ishikuro M, Ohseto H, Uruno A, Kobayashi T, Kodama EN, Hamanaka Y, Orui M, Ogishima S, Nagaie S, Fuse N, Sugawara J, Kuriyama S, Matsuda K, Izumi Y, Kinoshita K, Tamiya G, Hozawa A, Yamamoto M; ToMMo Investigators. Genetic risk, lifestyle adherence, and risk of developing hyperuricaemia in a Japanese population. Rheumatology (Oxford)<\/strong>, 64:2591-2600 (2025)<\/li>\n\n\n\n
  11. Sato T, Kawabata T, Kumondai M, Hayashi N, Komatsu H, Kikuchi Y, Onoguchi G, Sato Y, Nanatani K, Hiratsuka M, Maekawa M, Yamaguchi H, Abe T, Tomita H, Mano N. Effect of organic anion transporting polypeptide 1B1 on plasma concentration dynamics of Clozapine in patients with treatment-resistant schizophrenia. Int. J. Mol. Sci.<\/strong>, 25:13228 (2024)<\/li>\n\n\n\n
  12. Yamazaki S, Hishinuma E, Suzuki Y, Ueda A, Kijogi C, Nakayoshi T, Oda A, Saito S, Tadaka S, Kinoshita K, Maekawa M, Sato Y, Kumondai M, Mano N, Hirasawa N, Hiratsuka M. Functional significance of CYP2B6 gene rare allelic variants identified in Japanese individuals. Biochem. Pharmacol.<\/strong>, 229:116515 (2024)<\/li>\n\n\n\n
  13. Musyoka K, Chan CW, Gutierrez Rico EM, Omondi P, Kijogi C, Okai T, Kongere J, Ngara M, Kagaya W, Kanoi BN, Hiratsuka M, Kido Y, Gitaka J, Kaneko A. Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity. Drug Metab. Pharmacokinet.<\/strong>, 57:101029 (2024)<\/li>\n\n\n\n
  14. Kato K, Nakayoshi T, Hioki S, Hiratsuka M, Ishikawa Y, Kurimoto E, Oda A. Structural Impact Assessment of Cytochrome P450 2A13 Polymorphisms Using Molecular Dynamics Simulations. Biol. Pharm. Bull.<\/strong>, 47:620-628 (2024)<\/li>\n\n\n\n
  15. Shimizu M, Makiguchi M, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H. Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources. Drug Metab. Pharmacokinet.<\/strong>, 55:100539 (2024)<\/li>\n\n\n\n
  16. Tadaka S, Kawashima J, Hishinuma E, Saito S, Okamura Y, Otsuki A, Kojima K, Komaki S, Aoki Y, Kanno T, Saigusa D, Inoue J, Shirota M, Takayama J, Katsuoka F, Shimizu A, Tamiya G, Shimizu R, Hiratsuka M, Motoike IN, Koshiba S, Sasaki M, Yamamoto M, Kinoshita K. jMorp: Japanese Multi-Omics Reference Panel update report 2023. Nucleic Acids Res.<\/strong>, 52:D622-D632 (2024)<\/li>\n\n\n\n
  17. Sato Y, Hishinuma E, Yamazaki S, Ueda A, Kumondai M, Saito S, Tadaka S, Kinoshita K, Nakayoshi T, Oda A, Maekawa M, Mano N, Hirasawa N, Hiratsuka M. Functional characterization of 29 cytochrome P450 4F2 variants identified in a population of 8,380 Japanese subjects and assessment of arachidonic acid \u03c9-hydroxylation. Drug Metab. Dispos.<\/strong>, 51: 1561-1568 (2023)<\/li>\n\n\n\n
  18. Makiguchi M, Shimizu M, Yokota Y, Shimamura E, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H. Variants of flavin-containing monooxygenase 3 found in subjects in an updated database of genome resources. Drug Metab. Dispos.<\/strong>, 51:884-891 (2023)<\/li>\n\n\n\n
  19. Tsukagoshi E, Nakamura R, Tanaka Y, Maekawa K, Hiratsuka M, Asada H, Saito Y. Validation of a genotyping technique for a surrogate marker of HLA-B?58:01 for allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in the Japanese population. Drug Metab. Pharmacokinet.<\/strong>, 49:100495 (2023)<\/li>\n\n\n\n
  20. Kumondai M, Maekawa M, Hishinuma E, Sato Y, Sato T, Kikuchi M, Hiratsuka M, Mano N. Development of a simultaneous liquid chromatography-tandem mass spectrometry analytical method for urinary endogenous substrates and metabolites for predicting cytochrome P450 3A4 activity. Biol. Pharm. Bull.<\/strong>, 46:455-463 (2023)<\/li>\n\n\n\n
  21. Hishinuma E, Narita Y, Gutierrez Rico EM, Ueda A, Obuchi K, Tanaka Y, Saito S, Tadaka S, Kinoshita K, Maekawa M, Mano N, Nakayoshi T, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 12 dihydropyrimidinase allelic variants in Japanese individuals for the prediction of 5-fluorouracil treatment-related toxicity. Drug Metab. Dispos.<\/strong>, 51:165-173 (2023)<\/li>\n\n\n\n
  22. Kato K, Nakayoshi T, Nagura A, Hishinuma E, Hiratsuka M, Kurimoto E, Oda A. Structural investigation of pathogenic variants in dihydropyrimidinase using molecular dynamics simulations. J. Mol. Graph. Model.<\/strong>, 117:108288 (2022)<\/li>\n\n\n\n
  23. Shimizu M, Hirose N, Kato M, Sango H, Uenuma Y, Makiguchi M, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H. Further survey of genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found in an updated database of genome resources and identified by phenotyping for trimethylaminuria. Drug Metab. Pharmacokinet.<\/strong>, 46:100465 (2022)<\/li>\n\n\n\n
  24. Hishinuma E, Narita Y, Obuchi K, Ueda A, Saito S, Tadaka S, Kinoshita K, Maekawa M, Mano N, Hirasawa N, Hiratsuka M. Importance of rare DPYD genetic polymorphisms for 5-fluorouracil therapy in the Japanese population. Front. Pharmacol.<\/strong>, 13:930470 (2022)<\/li>\n\n\n\n
  25. Ganaha A, Hishinuma E, Kaname T, Hiratsuka M, Kondo S, Tono T. Rapid genetic diagnosis for Okinawan patients with Pendred syndrome using single-stranded tag hybridization chromatographic printed-array strip. J. Clin. Med.<\/strong>, 11:1099 (2022)<\/li>\n\n\n\n
  26. Siamoglou S, Koromina M, Hishinuma E, Yamazaki S, Tsermpini EE, Kordou Z, Fukunaga K, Chantratita W, Zhou Y, Lauschke V, Mushiroda T, Hiratsuka M, Patrinos GP. Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics. Pharmacol. Res.<\/strong>, 176:106087 (2022)<\/li>\n\n\n\n
  27. Ohneda K, Hiratsuka M, Kawame H, Nagami F, Suzuki Y, Suzuki K, Sato M, Uruno A, Sakurai-Yageta M, Hamanaka Y, Taira M, Ogishima S, Kuriyama S, Hozawa A, Tomita H, Minegishi N, Sugawara J, Danjo I, Nakamura T, Kobayashi T, Yamaguchi-Kabata Y, Tadaka S, Obara T, Hishinuma E, Mano N, Matsuura M, Sato Y, Honkura Y, Suzuki J, Katori Y, Kakuta Y, Masamune A, Aoki Y, Nakayama M, Kure S, Kinoshita K, Fuse N, Yamamoto M. A pilot study for return of individual pharmacogenomic results to population-based cohort study participants. Jpn. Med. Assoc. J.<\/strong>, 5:177-189 (2022)<\/li>\n\n\n\n
  28. Kato K, Nakayoshi T, Nokura R, Hosono H, Hiratsuka M, Ishikawa Y, Kurimoto E, Oda A. Deciphering structural alterations associated with activity reductions of genetic polymorphisms in cytochrome P450 2A6 using molecular dynamics simulations. Int. J. Mol. Sci.<\/strong>, 22:10119 (2021)<\/li>\n\n\n\n
  29. Kumondai M, Guti?rrez Rico EM, Hishinuma E, Nakanishi Y, Yamazaki S, Ueda A, Saito S, Tadaka S, Kinoshita K, Saigusa D, Nakayoshi T, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 21 rare allelic CYP1A2 variants identified in a population of 4773 Japanese individuals by assessing phenacetin O-deethylation. J. Pers. Med.<\/strong>, 11:690 (2021)<\/li>\n\n\n\n
  30. Shimizu M, Koibuchi N, Mizugaki A, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H. Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources. Drug Metab. Pharmacokinet.<\/strong>, 38:100387 (2021)<\/li>\n\n\n\n
  31. Kumondai M, Gutierrez Rico EM, Hishinuma E, Ueda A, Saito S, Tadaka S, Kinoshita K, Nakayoshi T, Oda A, Maekawa M, Mano N, Hirasawa N, Hiratsuka M. Functional assessment of 12 rare allelic CYP2C9 variants identified in a population of 4773 Japanese individuals. J. Pers. Med.<\/strong>, 11:94 (2021)<\/li>\n\n\n\n
  32. Kumondai M, Guti?rrez Rico EM, Hishinuma E, Ueda A, Saito S, Saigusa D, Tadaka S, Kinoshita K, Nakayoshi T, Oda A, Abe A, Maekawa M, Mano N, Hirasawa N, Hiratsuka M. Functional characterization of 40 CYP3A4 variants by assessing midazolam 1\u2032-hydroxylation and testosterone 6\u03b2-hydroxylation. Drug Metab. Dispos.<\/strong>, 49:212-220 (2021)<\/li>\n\n\n\n
  33. Isaka Y, Nishio S, Hishinuma E, Hiratsuka M, Usami S. Improvement of a Rapid and Highly Sensitive Method for the Diagnosis of the Mitochondrial m.1555A>G Mutation Based on a Single-Stranded Tag Hybridization Chromatographic Printed-Array Strip. Genet. Test. Mol. Biomarkers<\/strong>, 25:79-83 (2021)<\/li>\n\n\n\n
  34. Kumondai M, Hishinuma E, Guti?rrez Rico EM, Ito A, Nakanishi Y, Saigusa D, Hirasawa N, Hiratsuka M. Heterologous expression of high-activity cytochrome P450 in mammalian cells. Sci. Rep.<\/strong>, 10:14193 (2020)<\/li>\n\n\n\n
  35. Fukunaga K, Hishinuma E, Hiratsuka M, Kato K, Okusaka T, Saito T, Ikeda M, Yoshida T, Zembutsu H, Iwata N, Mushiroda T. Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population. J. Hum. Genet.<\/strong>, 66:139-149 (2020)<\/li>\n\n\n\n
  36. Gutierrez Rico EM, Kikuchi A, Saito T, Kumondai M, Hishinuma E, Kaneko A, Chan CW, Gitaka J, Nakayoshi T, Oda A, Hirasawa N, Hiratsuka M. CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity. Drug Metab. Pharmacokinet.<\/strong>, 35:85-101 (2020)<\/li>\n\n\n\n
  37. Shimizu M, Yoda H, Nakakuki K, Saso A, Saito I, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H. Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database. Drug Metab. Pharmacokinet.<\/strong>, 34:334-339 (2019)<\/li>\n\n\n\n
  38. Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke V. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J.<\/strong>, 19:115-126 (2019)<\/li>\n\n\n\n
  39. Watanabe T, Saito T, Guti?rrez Rico EM, Hishinuma E, Kumondai M, Maekawa M, Oda A, Saigusa D, Saito S, Yasuda J, Nagasaki M, Minegishi N, Yamamoto M, Yamaguchi H, Mano N, Hirasawa N, Hiratsuka M. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation. Biochem. Pharmacol.<\/strong>, 156:420-430 (2018)<\/li>\n\n\n\n
  40. Saito T, Gutierrez Rico EM, Kikuchi A, Kaneko A, Kumondai M, Akai F, Saigusa D, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation. Drug Metab. Pharmacokinet.<\/strong>, 33:250-257 (2018)<\/li>\n\n\n\n
  41. Kumondai M, Ito A, Hishinuma E, Kikuchi A, Saito T, Takahashi M, Tsukada C, Saito S, Yasuda J, Nagasaki M, Minegishi N, Yamamoto M, Kaneko A, Teramoto I, Kimura M, Hirasawa N, Hiratsuka M. Development and application of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS). Drug Metab. Pharmacokinet.<\/strong>, 33:258-263 (2018)<\/li>\n\n\n\n
  42. Jukic MM, Lauschke VM, Saito T, Hiratsuka M, Ingelman-Sundberg M. Functional characterization of CYP2D7 gene variants. Pharmacogenomics<\/strong>, 19:931-936 (2018)<\/li>\n\n\n\n
  43. Hishinuma E, Narita Y, Saito S, Maekawa M, Akai F, Nakanishi Y, Yasuda J, Nagasaki M, Yamamoto M, Yamaguchi H, Mano N, Hirasawa N, Hiratsuka M. Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1,070 Japanese individuals. Drug Metab. Dispos.<\/strong>, 46:1083-1090 (2018)<\/li>\n\n\n\n
  44. Saito T, Kikuchi A, Kaneko A, Isozumi R, Teramoto I, Kimura M, Hirasawa N, Hiratsuka M. Rapid and sensitive multiplex single-tube nested PCR for the identification of five human Plasmodium species. Parasitol. Int.<\/strong>, 67:277-283 (2018)<\/li>\n\n\n\n
  45. Kumondai M, Hosono H, Maekawa M, Yamaguchi H, Mano N, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation. Drug Metab. Pharmacokinet.<\/strong>, 33:82-89 (2018)<\/li>\n\n\n\n
  46. Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, Rodr?guez-Antona C. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet. Med.<\/strong>, 20:622-629 (2018)<\/li>\n\n\n\n
  47. Hishinuma E, Akai F, Narita Y, Maekawa M, Yamaguchi H, Mano N, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 21 allelic variants of dihydropyrimidinase. Biochem. Pharmacol.<\/strong>, 143:118-128 (2017)<\/li>\n\n\n\n
  48. Watanabe Y, Fukuyoshi S, Kato K, Hiratsuka M, Yamaotsu N, Hirono S, Gouda H, Oda A. Investigation of substrate recognition for cytochrome P450 1A2 mediated by water molecules using docking and molecular dynamics simulations. J. Mol. Graph. Model.<\/strong>, 74:326-336 (2017)<\/li>\n\n\n\n
  49. Hosono H, Kumondai M, Maekawa M, Yamaguchi H, Mano N, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 34 CYP2A6 allelic variants by assessment of nicotine C- oxidation and coumarin 7-hydroxylation activities. Drug Metab. Dispos.<\/strong>, 45:279-285 (2017)<\/li>\n\n\n\n
  50. Kumondai M, Hosono H, Orikasa K, Arai Y, Arai T, Sugimura H, Ozono S, Sugiyama T, Takayama T, Sasaki T, Hirasawa N, Hiratsuka M. CYP2A13 genetic polymorphisms in relation to the risk of bladder cancer in Japanese smokers. Biol. Pharm. Bull.<\/strong>, 39:1683-1686 (2016)<\/li>\n\n\n\n
  51. Watanabe Y, Fukuyoshi S, Hiratsuka M, Yamaotsu N, Hirono S, Takahashi O, Oda A. Prediction of three-dimensional structures and structural flexibilities of wild-type and mutant cytochrome P450 1A2 using molecular dynamics simulations. J. Mol. Graph. Model.<\/strong>, 68:48-56 (2016)<\/li>\n\n\n\n
  52. Fukuyoshi S, Kometani M, Watanabe Y, Hiratsuka M, Yamaotsu N, Hirono S, Manabe N, Takahashi O, Oda A. Molecular dynamics simulations to investigate the influences of amino acid mutations on protein three-dimensional structures of cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62. PLoS One<\/strong>, 11:e0152946 (2016)<\/li>\n\n\n\n
  53. Kumondai M, Hosono H, Orikasa K, Arai Y, Arai T, Sugimura H, Ozono S, Sugiyama T, Takayama T, Sasaki T, Hirasawa N, Hiratsuka M. Genetic polymorphisms of CYP2A6 in a case-control study on bladder cancer in Japanese smokers. Biol. Pharm. Bull.<\/strong>, 39:84-89 (2016)<\/li>\n\n\n\n
  54. Tsukada C, Saito T, Maekawa M, Mano N, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6\u03b1-hydroxylation and amodiaquine N-deethylation. Drug Metab. Pharmacokinet.<\/strong>, 30:366-373 (2015)<\/li>\n\n\n\n
  55. Hosono H, Kumondai M, Arai T, Sugimura H, Sasaki T, Hirasawa N, Hiratsuka M. CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers. Drug Metab. Pharmacokinet.<\/strong>, 30:263-268 (2015)<\/li>\n\n\n\n
  56. Hiratsuka M, Yamashita H, Akai F, Hosono H, Hishinuma E, Hirasawa N, Mori T. Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity. PLoS One<\/strong>, 10:e0124818 (2015)<\/li>\n\n\n\n
  57. Ito M, Katono Y, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 20 allelic variants of CYP1A2. Drug Metab. Pharmacokinet.<\/strong>, 30:247-252 (2015)<\/li>\n\n\n\n
  58. Akai F, Hosono H, Hirasawa N, Hiratsuka M. Novel single nucleotide polymorphisms of the dihydropyrimidinase gene (DPYS) in Japanese individuals. Drug Metab. Pharmacokinet.<\/strong>, 30:127-129 (2015)<\/li>\n\n\n\n
  59. Saito T, Honda M, Saigusa D, Suzuki N, Tomioka Y, Hirasawa N, Hiratsuka M. Functional characterization of 10 CYP4A11 allelic variants to evaluate the effect of genotype on arachidonic acid \u03c9-hydroxylation. Drug Metab. Pharmacokinet.<\/strong>, 30:119-122 (2015)<\/li>\n\n\n\n
  60. Takahashi M, Saito T, Ito M, Tsukada C, Katono Y, Hosono H, Maekawa M, Shimada M, Mano N, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. Pharmacogenomics J.<\/strong>, 15:26-32 (2015)<\/li>\n\n\n\n
  61. Kobayashi K, Takahashi O, Hiratsuka M, Yamaotsu N, Hirono S, Watanabe Y, Oda A. Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation. PLoS One<\/strong>, 9:e96789 (2014)<\/li>\n\n\n\n
  62. Muroi Y, Saito T, Takahashi M, Sakuyama K, Niinuma Y, Ito M, Tsukada C, Ohta K, Endo Y, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity. Drug Metab. Pharmacokinet.<\/strong>, 29:360-366 (2014)<\/li>\n\n\n\n
  63. Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, Hiratsuka M. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J.<\/strong>, 14:107-114 (2014)<\/li>\n\n\n\n
  64. Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur. J. Clin. Pharmacol.<\/strong>, 68:397-406 (2012)<\/li>\n\n\n\n
  65. Honda M, Muroi Y, Tamaki Y, Saigusa D, Suzuki N, Tomioka Y, Matsubara Y, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of CYP2B6 allelic variants in demethylation of anti-malarial artemether. Drug Metab. Dispos.<\/strong>, 39:1860-1865 (2011)<\/li>\n\n\n\n
  66. Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, Matsubara Y, Kanno S, Ishikawa M, Hirasawa N, Hiratsuka M. Association between cancer risk and drug metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in Japanese cases of lung cancer. Drug Metab. Pharmacokinet.<\/strong>, 26:516-522 (2011)<\/li>\n\n\n\n
  67. Tamaki Y, Honda M, Muroi Y, Arai T, Sugimura H, Matsubara Y, Kanno S, Ishikawa M, Hirasawa N, Hiratsuka M. Novel single nucleotide polymorphism of CYP2A13 gene in a Japanese population. Drug Metab. Pharmacokinet.<\/strong>, 26:544-547 (2011)<\/li>\n<\/ol>\n\n\n\n

    \u5b66\u4f1a\u767a\u8868<\/h3>\n\n\n\n

    \u56fd\u969b\u5b66\u4f1a\u62db\u5f85\u8b1b\u6f14<\/h4>\n\n\n\n
      \n
    1. Masahiro Hiratsuka, CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Kenyan and Ni-Vanuatu population. The 5th Africa International Biotechnology and Biomedical Conference (AIBBC 2021),(November 12 2021, Kisumu, Kenya)<\/li>\n\n\n\n
    2. Masahiro Hiratsuka, Pharmacogenomic Research for Precision Medicine, Sichuan University-Tohoku University Pharmaceutical Sciences Collaboration Symposium, (May 5 2019, Chengdu, China)<\/li>\n\n\n\n
    3. Masahiro Hiratsuka, Pharmacogenomics of antimalarial drugs, KI-Japan joint seminar \u201cMalaria research: innovations and global malaria eradication (November 13 2018, Stockholm, Sweden)<\/li>\n\n\n\n
    4. Masahiro Hiratsuka, Pharmacogenomic Research for Precision Medicine, The 4th Japan-Taiwan Joint Symposium for Pharmaceutical Sciences, (August 31 2018, Sapporo, Japan)<\/li>\n\n\n\n
    5. Masahiro Hiratsuka, Single Nucleotide Polymorphism Discovery in Drug-Metabolizing Enzyme Genes and Functional Characterization of the Allelic Variant Proteins, 2013 International Conference on Pharmacogenomics (Feb. 1, 2013, Busan, Republic of Korea)<\/li>\n\n\n\n
    6. Masahiro Hiratsuka, Functional Characterization of Xanthine Oxidase Allelic Variants, 13th International Symposium on Purine and Pyrimidine Metabolism in Man, PP09(June 21-24 2009, Stockholm, Sweden)<\/li>\n<\/ol>\n\n\n\n

      \u56fd\u5185\u5b66\u4f1a\u62db\u5f85\u8b1b\u6f14\u30fb\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0<\/h4>\n\n\n\n
        \n
      1. \u5e73\u585a\u771f\u5f18\u3001\u300c\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u7814\u7a76\u306e\u73fe\u72b6\u3001\u8ab2\u984c\u3001\u5c55\u671b\u300d\u3001\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u85ac\u7269\u4ee3\u8b1d\u7814\u7a76\u306e\u8ab2\u984c\u3068\u4eca\u5f8c\u306e\u5c55\u671b\u300d\u3001\u65e5\u672c\u85ac\u7269\u52d5\u614b\u5b66\u4f1a\u7b2c40\u56de\u5e74\u4f1a\u3001\uff082025\u5e7410\u670821\u65e5\u3001\u4eac\u90fd\uff09<\/li>\n\n\n\n
      2. \u5e73\u585a\u771f\u5f18\u3001\u300cPGx\u691c\u67fb\u306e\u73fe\u5728\u5730\uff1a\u57fa\u790e\u3068\u81e8\u5e8a\u80cc\u666f\u306e\u30aa\u30fc\u30d0\u30fc\u30d3\u30e5\u30fc\u300d\u3001\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u691c\u67fb\u306e\u6700\u65b0\u52d5\u5411\u301c\u81e8\u5e8a\u5b9f\u8df5\u306b\u5411\u3051\u305f\u8ab2\u984c\u3068\u5c55\u671b\u300d\u3001\u7b2c34\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a\uff082024\u5e7411\u67084\u65e5\u3001\u5e55\u5f35\uff09<\/li>\n\n\n\n
      3. \u5e73\u585a\u771f\u5f18\u3001\u300c\u30d0\u30a4\u30aa\u30d0\u30f3\u30af\u3092\u6d3b\u7528\u3057\u305fPGx\u7814\u7a76\u306b\u3088\u308a\u52b9\u679c\u7684\u30fb\u52b9\u7387\u7684\u306a\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u3092\u5b9f\u73fe\u3059\u308b\u57fa\u76e4\u7814\u7a76\u300d\u3001\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u85ac\u5264\u5e2b\u30fb\u85ac\u5b66\u7814\u7a76\u8005\u304c\u5148\u5c0e\u3059\u308bAMED\u7814\u7a76\u4e8b\u696d\u300d\u3001\u7b2c34\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a\uff082024\u5e7411\u67083\u65e5\u3001\u5e55\u5f35\uff09<\/li>\n\n\n\n
      4. \u5e73\u585a\u771f\u5f18\u3001\u300c\u30d0\u30a4\u30aa\u30d0\u30f3\u30af\u3092\u6d3b\u7528\u3057\u305fPGx\u89e3\u6790\u306b\u3088\u308b\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u300d\u3001\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u30fb\u7b2c7\u56de\u85ac\u7406\u30b2\u30ce\u30df\u30af\u30b9\u30bb\u30df\u30ca\u30fc\uff082024\u5e747\u67081\u65e5\u3001\u30aa\u30f3\u30e9\u30a4\u30f3\uff09<\/li>\n\n\n\n
      5. \u5e73\u585a\u771f\u5f18\u3001\u7279\u5225\u8b1b\u6f14\u300c\u4e00\u822c\u4f4f\u6c11\u30d0\u30a4\u30aa\u30d0\u30f3\u30af\u3092\u6d3b\u7528\u3057\u305f\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u7814\u7a76\u3068\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u3078\u306e\u5fdc\u7528\u300d\u3001\u7b2c55\u56de\u65e5\u672c\u85ac\u5264\u5e2b\u4f1a\u5b66\u8853\u5927\u4f1a\uff082022\u5e7410\u67089\u65e5\u3001\u4ed9\u53f0\uff09<\/li>\n\n\n\n
      6. \u5e73\u585a\u771f\u5f18\u3001\u5e02\u6c11\u516c\u958b\u8b1b\u5ea7\u300c\u907a\u4f1d\u3067\u5909\u308f\u308b\u533b\u85ac\u54c1\u306e\u52b9\u679c\u3068\u526f\u4f5c\u7528\u300d\u3001\u7b2c24\u56de\u65e5\u672c\u533b\u85ac\u54c1\u60c5\u5831\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff082022\u5e747\u67089-10\u65e5\u3001\u30aa\u30f3\u30e9\u30a4\u30f3\uff09<\/li>\n\n\n\n
      7. \u5e73\u585a\u771f\u5f18\u3001\u300c\u30d0\u30a4\u30aa\u30d0\u30f3\u30af\u3092\u6d3b\u7528\u3057\u305f\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u63a2\u7d22\u3068\u85ac\u7269\u6cbb\u7642\u3078\u306e\u5fdc\u7528\u300d\u3001\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u7b2c6\u56de \u81e8\u5e8a\u5316\u5b66\u306e\u9032\u6b69\u304c\u5909\u3048\u308b\u85ac\u7269\u6cbb\u7642\u300d\uff5e\u6700\u5148\u7aef\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u691c\u67fb\u306b\u3088\u308b\u65b0\u305f\u306a\u308b\u500b\u5225\u5316\u7642\u6cd5\u306e\u5275\u51fa\uff5e\u3001\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c142\u56de\u5e74\u4f1a(2022\u5e743\u670825\u221228\u65e5\u3001\u540d\u53e4\u5c4b\u3001\u30aa\u30f3\u30e9\u30a4\u30f3)<\/li>\n\n\n\n
      8. \u5e73\u585a\u771f\u5f18\u3001\u6559\u80b2\u8b1b\u6f14\u300c\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\uff08PGx\uff09\u89e3\u6790\u306b\u3088\u308b\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u300d\u3001\u65e5\u672c\u75c5\u9662\u85ac\u5264\u5e2b\u4f1a\u6771\u5317\u30d6\u30ed\u30c3\u30af\u7b2c10\u56de\u5b66\u8853\u5927\u4f1a\uff082020\u5e746\u670830\u65e5\u8a8c\u4e0a\u958b\u50ac\uff09<\/li>\n\n\n\n
      9. \u5e73\u585a\u771f\u5f18\u3001\u5b66\u8853\u8b1b\u6f14\uff1a\u30b2\u30ce\u30e0\u60c5\u5831\u3092\u6d3b\u7528\u3057\u305f\u672a\u6765\u578b\u533b\u7642\u3068\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u306e\u6700\u524d\u7dda\u3001\u5bae\u57ce\u770c\u85ac\u5264\u5e2b\u5b66\u8853\u30d5\u30a9\u30fc\u30e9\u30e0\uff082019\u5e7411\u670810\u65e5\u3001\u4ed9\u53f0\uff09<\/li>\n\n\n\n
      10. \u5e73\u585a\u771f\u5f18\u3001\u65e5\u672c\u8033\u79d1\u5b66\u4f1a\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u85ac\u5264\u6027\u96e3\u8074\u30ef\u30fc\u30ad\u30f3\u30b0\u30b0\u30eb\u30fc\u30d7\u5831\u544a\u3001\u6771\u5317\u30e1\u30c7\u30a3\u30ab\u30eb\u30fb\u30e1\u30ac\u30d0\u30f3\u30af\u6a5f\u69cb\u30fb\u907a\u4f1d\u60c5\u5831\u56de\u4ed8\u4e8b\u696d\u306b\u304a\u3051\u308b\u53d6\u308a\u7d44\u307f\u3001\u65e5\u672c\u8033\u79d1\u5b66\u4f1a\u7b2c29\u56de\u5b66\u8853\u8b1b\u6f14\u4f1a\uff082019\u5e7410\u670810-12\u65e5\u3001\u5c71\u5f62\uff09<\/li>\n\n\n\n
      11. \u5e73\u585a\u771f\u5f18\u3001\u65e5\u672c\u8033\u79d1\u5b66\u4f1a\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u85ac\u5264\u6027\u96e3\u8074\u30ef\u30fc\u30ad\u30f3\u30b0\u30b0\u30eb\u30fc\u30d7\u5831\u544a\u3001\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u907a\u4f1d\u5b50\u5909\u7570\u306e\u7c21\u4fbf\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u691c\u67fb\u3001\u65e5\u672c\u8033\u79d1\u5b66\u4f1a\u7b2c28\u56de\u5b66\u8853\u8b1b\u6f14\u4f1a\uff082018\u5e7410\u67083-6\u65e5\u3001\u5927\u962a\uff09<\/li>\n\n\n\n
      12. \u5e73\u585a\u771f\u5f18\u3001\u6559\u80b2\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u30b2\u30ce\u30e0\u85ac\u7406\u5b66\u3092\u5229\u7528\u3057\u305f\u500b\u5225\u5316\u533b\u7642\u3001\u65e5\u672c\u4eba\u985e\u907a\u4f1d\u5b66\u4f1a\u7b2c63\u56de\u5927\u4f1a\uff082018\u5e7410\u670810-13\u65e5\u3001\u6a2a\u6d5c\uff09<\/li>\n\n\n\n
      13. \u5e73\u585a\u771f\u5f18\u3001\u65e5\u672c\u4eba\u96c6\u56e3\u306e\u5168\u30b2\u30ce\u30e0\u89e3\u6790\u304b\u3089\u898b\u3048\u3066\u304f\u308b\u85ac\u7269\u4ee3\u8b1d\u9175\u7d20\u6d3b\u6027\u306e\u500b\u4eba\u5dee\u3001\u7b2c24\u56de\u30af\u30ed\u30de\u30c8\u30b0\u30e9\u30d5\u30a3\u30fc\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 (2017\u5e746\u670814-16\u65e5\u3001\u4ed9\u53f0)<\/li>\n\n\n\n
      14. \u5e73\u585a\u771f\u5f18\u3001\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u3092\u76ee\u6307\u3057\u305f\u65e5\u672c\u4eba\u5168\u30b2\u30ce\u30e0\u30ea\u30d5\u30a1\u30ec\u30f3\u30b9\u30d1\u30cd\u30eb\u306b\u3088\u308b\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30c7\u30fc\u30bf\u89e3\u6790\u3001\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c137\u5e74\u4f1a (2017\u5e743\u670825-27\u65e5\u3001\u4ed9\u53f0)<\/li>\n\n\n\n
      15. \u5e73\u585a\u771f\u5f18\u3001\u85ac\u7269\u4ee3\u8b1d\u9175\u7d20\u306e\u907a\u4f1d\u5b50\u591a\u578b\u30d0\u30ea\u30a2\u30f3\u30c8\u30bf\u30f3\u30d1\u30af\u8cea\u306e\u6a5f\u80fd\u5909\u5316\u3001\u65e5\u672c\u85ac\u7269\u52d5\u614b\u5b66\u4f1a\u7b2c31\u56de\u5e74\u4f1a\uff082016\u5e7410\u670813\u65e5\u3001\u677e\u672c\uff09<\/li>\n\n\n\n
      16. \u5e73\u585a\u771f\u5f18\u3001\u5927\u898f\u6a21\u5168\u30b2\u30ce\u30e0\u30b7\u30fc\u30af\u30a8\u30f3\u30b9\u89e3\u6790\u304b\u3089\u898b\u3048\u3066\u304f\u308b\u85ac\u7269\u4ee3\u8b1d\u9175\u7d20\u6d3b\u6027\u306e\u500b\u4eba\u5dee\u3001\u7b2c89\u56de\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5927\u4f1a\uff082016\u5e749\u670826\u65e5\u3001\u4ed9\u53f0\uff09<\/li>\n\n\n\n
      17. \u5e73\u585a\u771f\u5f18\u3001\u30b2\u30ce\u30e0\u60c5\u5831\u3092\u6d3b\u7528\u3059\u308b\u85ac\u5b66\u751f\u30fb\u85ac\u5264\u5e2b\u306e\u80b2\u6210\u3001\u7b2c26\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a\uff082016\u5e749\u670817\u65e5\u3001\u4eac\u90fd\uff09<\/li>\n\n\n\n
      18. \u5e73\u585a\u771f\u5f18\u3001\u5e73\u621028\u5e74\u5ea6\u65e5\u672c\u85ac\u5b66\u4f1a\u5b66\u8853\u632f\u8208\u8cde\u53d7\u8cde\u8b1b\u6f14\u3001\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u3092\u76ee\u6307\u3057\u305f\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u89e3\u6790\u306b\u95a2\u3059\u308b\u7814\u7a76\u3001\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c136\u5e74\u4f1a\uff082016\u5e743\u670827\u65e5\u3001\u6a2a\u6d5c\uff09<\/li>\n\n\n\n
      19. \u5e73\u585a\u771f\u5f18\u3001\u6297\u304c\u3093\u5264\u6cbb\u7642\u306b\u304a\u3051\u308b\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u3001\u6771\u5317\u5927\u5b66\u5927\u5b66\u9662\u85ac\u5b66\u7814\u7a76\u79d1\u30fb\u56fd\u7acb\u533b\u85ac\u54c1\u98df\u54c1\u885b\u751f\u7814\u7a76\u6240\u9023\u643a\u5927\u5b66\u9662\u300c\u533b\u85ac\u54c1\u8a55\u4fa1\u5b66\u9023\u643a\u8b1b\u5ea7\u300d\u30ad\u30c3\u30af\u30aa\u30d5\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u30b2\u30ce\u30e0\u60c5\u5831\u306b\u57fa\u3065\u304f\u30ea\u30b9\u30af\u8a55\u4fa1\u300d\uff082014\u5e746\u67083\u65e5\u3001\u6771\u4eac\uff09<\/li>\n\n\n\n
      20. \u5e73\u585a\u771f\u5f18\u3001\u907a\u4f1d\u5b50\u591a\u578b\u304c\u539f\u56e0\u3068\u306a\u308b\u533b\u85ac\u54c1\u76f8\u4e92\u4f5c\u7528\u3001\u7b2c69\u56de\u533b\u85ac\u54c1\u76f8\u4e92\u4f5c\u7528\u7814\u7a76\u4f1a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff082014\u5e745\u670831\u65e5\u3001\u4ed9\u53f0\uff09<\/li>\n\n\n\n
      21. \u5e73\u585a\u771f\u5f18\u3001\u6559\u80b2\u8b1b\u6f14\uff1a\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\uff08PGx\uff09\u60c5\u5831\u3092\u5229\u7528\u3057\u305f\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u306e\u5c55\u958b\u3001\u7b2c64\u56de\u65e5\u672c\u96fb\u6c17\u6cf3\u52d5\u5b66\u4f1a\u7dcf\u4f1a\uff082013\u5e7411\u670815-16\u65e5\u3001\u4ed9\u53f0\uff09<\/li>\n\n\n\n
      22. \u5e73\u585a\u771f\u5f18\u3001PGx\u306b\u7cbe\u901a\u3057\u305f\u5148\u5c0e\u7684\u6b21\u4e16\u4ee3\u578b\u85ac\u5264\u5e2b\u80b2\u6210\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u69cb\u7bc9\u3001\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u85ac\u5264\u5e2b\u304c\u62c5\u3046\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u306e\u73fe\u5728\u3068\u672a\u6765\u300d\u3001\u7b2c23\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a(2013\u5e749\u670821-22\u65e5\u3001\u4ed9\u53f0)<\/li>\n\n\n\n
      23. \u5e73\u585a\u771f\u5f18\u3001\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\uff08PGx\uff09\u306b\u7cbe\u901a\u3057\u305f\u85ac\u5264\u5e2b\u80b2\u6210\u306b\u5411\u3051\u305f\u7814\u7a76\u30fb\u6559\u80b2\u4f53\u5236\u306e\u6574\u5099\u3001\u533b\u7642\u85ac\u5b66\u30d5\u30a9\u30fc\u30e9\u30e0\/\u7b2c21\u56de\u30af\u30ea\u30cb\u30ab\u30eb\u30d5\u30a1\u30fc\u30de\u30b7\u30fc\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0(2013\u5e747\u670820-21\u65e5\u3001\u91d1\u6ca2)<\/li>\n\n\n\n
      24. \u5e73\u585a\u771f\u5f18\u3001\u5e73\u621024\u5e74\u5ea6\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5b66\u8853\u8ca2\u732e\u8cde\u53d7\u8cde\u8b1b\u6f14\u3001\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u89e3\u6790\u306b\u3088\u308b\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u306e\u63a8\u9032\u3001\u7b2c22\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a(2012\u5e7410\u670827-28\u65e5\u3001\u65b0\u6f5f)<\/li>\n\n\n\n
      25. \u5e73\u585a\u771f\u5f18\u3001\u907a\u4f1d\u5b50\u591a\u578b\u60c5\u5831\u306b\u57fa\u3065\u304f\u85ac\u7269\u4ee3\u8b1d\u9175\u7d20\u30d0\u30ea\u30a2\u30f3\u30c8\u306e\u9175\u7d20\u53cd\u5fdc\u901f\u5ea6\u8ad6\u7684\u6a5f\u80fd\u89e3\u6790\u3001\u65e5\u672c\u85ac\u5b66\u4f1a\u6771\u5317\u652f\u90e8\u3000\u7b2c10\u56de\u533b\u7642\u7cfb\u85ac\u5b66\u82e5\u624b\u7814\u7a76\u8005\u30bb\u30df\u30ca\u30fc (2011\u5e749\u6708\u3001\u4ed9\u53f0)<\/li>\n\n\n\n
      26. \u5e73\u585a\u771f\u5f18\u3001\u5e73\u621022\u5e74\u5ea6\u65e5\u672c\u85ac\u7269\u52d5\u614b\u5b66\u4f1a\u5968\u52b1\u8cde\u53d7\u8cde\u8b1b\u6f14\u3001\u85ac\u7269\u4ee3\u8b1d\u9175\u7d20\u907a\u4f1d\u5b50\u306e\uff33\uff2e\uff30\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3068\u30d0\u30ea\u30a2\u30f3\u30c8\u9175\u7d20\u306e\u6a5f\u80fd\u5909\u5316\u89e3\u6790\u306b\u95a2\u3059\u308b\u7814\u7a76\u3001\u65e5\u672c\u85ac\u7269\u52d5\u614b\u5b66\u4f1a\u7b2c25\u56de\u5e74\u4f1a(2010\u5e7410\u67087-9\u65e5)<\/li>\n<\/ol>\n\n\n\n

        \u56fd\u969b\u5b66\u4f1a\u53e3\u982d\u767a\u8868<\/h4>\n\n\n\n
          \n
        1. SHUKI YAMAZAKI, Functional characterization of 31 CYP2B6 rare variants identified in 8,380 Japanese individuals, The 8th Taiwan-Japan Joint Symposium for Pharmaceutical Sciences (Sep. 1, 2023, Taipei, Taiwan)<\/li>\n<\/ol>\n\n\n\n

          \u56fd\u969b\u5b66\u4f1a\u30dd\u30b9\u30bf\u30fc\u767a\u8868<\/h4>\n\n\n\n
            \n
          1. Suzuki Y, Hishinuma E, Kumondai M, Nakayoshi T, Oda A, Saito S, Tadaka S, Kinoshita K, Hirasawa N, Hiratsuka M, Functional characterization of 20 rare variants of CYP2A6 by assessing coumarin 7-hydroxylation, 2023 International Joint Meeting of the 23rd International Conference in Cytochrome P450 and the 38th Annual Meeting of the Japanese Society for the Study of Xenobiotics (Shizuoka, Japan, 2023, Sep. 25-29)<\/li>\n\n\n\n
          2. Obuchi K, Hishinuma E, Ueda A, Maekawa M, Saito S, Kinoshita K, Hiratsuka M, Functional characterization of seven dihydropyrimidinase allelic variants in Japanese individuals for the prediction of 5-fluorouracil treatment-related toxicity, 2023 International Joint Meeting of the 23rd International Conference in Cytochrome P450 and the 38th Annual Meeting of the Japanese Society for the Study of Xenobiotics (Shizuoka, Japan, 2023, Sep. 25-29)<\/li>\n\n\n\n
          3. Yamazaki S, Hishinuma E, Ueda A, Masamitsu M, Sato Y, Kumondai M, Mano N, Nakayoshi T, Oda A, Saito S, Tadaka S, Kinoshita K, Hirasawa N, Hiratsuka M, Functional characterization of 31 CYP2B6 rare variants identified in 8,380 Japanese individuals, 2023 International Joint Meeting of the 23rd International Conference in Cytochrome P450 and the 38th Annual Meeting of the Japanese Society for the Study of Xenobiotics (Shizuoka, Japan, 2023, Sep. 25-29)<\/li>\n\n\n\n
          4. Kumondai M, Ito A, Hishinuma E, Saito T,Ishida N, Minegishi N, Saito S, Kinoshita K,Yamamoto M, Hirasawa N, Hiratsuka M, Rapid and sensitive genotyping method for thiopurines-related pharmacogene variants using single-stranded tag hybridization chromatographic printed-array strip (STH-PAS), Tohoku Forum for Creativity Thematic Program 2019 Cancer-from Biology to Acceptance (Sendai, Japan, 2019, Dec 2-3)<\/li>\n\n\n\n
          5. Kumondai M, Ito A, Saito T, Saito S, Yasuda J, Nagasaki M, Kinoshita K, Yamamoto M, Oda A, Hirasawa N, Hiratsuka M, Functional characterization of 11 allelic variants of CYP2C9 identified in 3554 Japanese individuals, International Conferences on Cytochrome P450 (Brisbane, Australia, 2019, June 23-27)<\/li>\n\n\n\n
          6. Hishinuma E, Narita Y, Saito S, Maekawa M, Akai F, Nakanishi Y, Yasuda J, Nagasaki M, Yamamoto M, Yamaguchi H, Mano N, Hirasawa N, Hiratsuka M, Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1,070 Japanese individuals, 2018 International Meeting on 22nd MDO and 33rd JSSX (Kanazawa, Japan, 2018, October 1-5)<\/li>\n\n\n\n
          7. Ito A, Kumondai M, Hishinuma E, Kikuchi A, Saito T, Takahashi M, Tsukada C, Saito S, Yasuda J, Nagasaki M, Minegishi M, Yamamoto M, Kaneko A, Teramoto I, Kimura M, Hirasawa N, Hiratsuka M, Development of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS), 2018 International Meeting on 22nd MDO and 33rd JSSX (Kanazawa, Japan, 2018, October 1-5)<\/li>\n\n\n\n
          8. Hishinuma E, Akai F, Maekawa M, Mano N, Hirasawa N, Hiratsuka M, Functional characterization of 21 allelic variants of dihydropyrimidinase, 6th FIP Pharmaceutical Sciences World Congress (PSWC) (Stockholm, Sweden, 2017, May 21-24)<\/li>\n\n\n\n
          9. M. Ito, Y. Katono, A. Oda, N. Hirasawa, M. Hiratsuka, Functional Characterization of 20 Allelic Variants of CYP1A2, 12th International Symposium on Cytochrome P450 Biodiversity and Biotechnology (Kyoto, Japan, 2014, September 24-28)<\/li>\n\n\n\n
          10. C. Tsukada, A. Oda, M. Maekawa, N. Mano, N. Hirasawa, M. Hiratsuka, Functional characterization of 12 allelic variants of CYP2C8 involved in paclitaxel 6\u03b1-hydroxylation and amodiaquine N-deethylation, 12th International Symposium on Cytochrome P450 (Kyoto, Japan, 2014, September 24-28)<\/li>\n\n\n\n
          11. H. Hosono, H. Sugimura, T. Arai, N. Hirasawa, M. Hiratsuka, CYP2A6 polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers, 20th MDO Meeting (Germany, 2014, May 18-22)<\/li>\n\n\n\n
          12. M. Hiratsuka, Y Muroi, T Saito, M Takahashi, Y Niinuma, M Ito, C Tsukada, N Hirasawa, Functional characterization of 50 CYP2D6 allelic variants with regard to 4-hydroxylation of N-desmethyltamoxifen, 19th MDO and 12th European ISSX Meeting (Netherland, 2012, June 17-21)<\/li>\n<\/ol>\n\n\n\n

            \u56fd\u5185\u5b66\u4f1a\u53e3\u982d\u767a\u8868<\/h4>\n\n\n\n

            \u56fd\u5185\u5b66\u4f1a\u30dd\u30b9\u30bf\u30fc\u767a\u8868<\/h4>\n\n\n\n
              \n
            1. \u5bfa\u5185\u5065\u4eba\u3001\u83f1\u6cbc\u82f1\u53f2\u3001\u4f0a\u85e4\u7531\u5b63\u7d75\u3001\u5897\u7530\u6df3\u3001\u5c0f\u6797\u9686\u4e4b\u3001\u9ad8\u91ce\u5229\u5b9f\u3001\u4e0a\u91ce\u8cb4\u4e4b\u3001\u52a0\u85e4\u307f\u3069\u308a\u3001\u524d\u5ddd\u6b63\u5145\u3001\u5e73\u585a\u771f\u5f18\u3001DPYD\u30ec\u30a2\u30d0\u30ea\u30a2\u30f3\u30c8\u306b\u3088\u308bDPD\u6d3b\u6027\u6b20\u640d\u304c\u5f15\u304d\u8d77\u3053\u30595-FU\u904e\u5270\u66dd\u9732\u3068\u91cd\u7be4\u526f\u4f5c\u7528\u306e\u95a2\u9023\u3001\u7b2c46\u56de\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012025\u5e7412\u67085-6\u65e5\u3001\u6771\u4eac<\/li>\n<\/ol>\n\n\n\n

              \u305d\u306e\u4ed6<\/h3>\n\n\n\n

              \u7dcf\u8aac<\/h4>\n\n\n\n
                \n
              1. \u304c\u3093\u5316\u5b66\u7642\u6cd5\u306b\u304a\u3051\u308b\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9 – \u85ac\u7269\u4ee3\u8b1d\u9175\u7d20\u306e\u907a\u4f1d\u5b50\u591a\u578b\u306b\u30d5\u30a9\u30fc\u30ab\u30b9\u3057\u3066\u3001\u5e73\u585a\u771f\u5f18\u3001\u533b\u5b66\u306e\u3042\u3086\u307f\u3001283(7):696-700 (2022)<\/li>\n\n\n\n
              2. \u7279\u96c6\uff1a\u907a\u4f1d\u5b50\u8a3a\u65ad\u306e\u73fe\u72b6\u3068\u672a\u6765\uff1a\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9-\u30b2\u30ce\u30e0\u85ac\u7406\u5b66\u3001\u5e73\u585a\u771f\u5f18\u3001\u65e5\u672c\u533b\u5e2b\u4f1a\u96d1\u8a8c\u3001149(11):1981-1984 (2021)<\/li>\n\n\n\n
              3. In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and \u03b2-Ureidopropionase. Hishinuma E, Guti\u00e9rrez Rico E, Hiratsuka M. J Clin Med., 9:E2342 (2020)<\/li>\n\n\n\n
              4. \u65e5\u672c\u4eba\u3092\u4e3b\u5bfe\u8c61\u3068\u3057\u305f\u300c\u533b\u85ac\u54c1\u306e\u975e\u81e8\u5e8a\u53ca\u3073\u81e8\u5e8a\u7b2c\u2160\u76f8\u8a66\u9a13\u306b\u304a\u3051\u308b\u907a\u4f1d\u5b50\u591a\u578b\u8a55\u4fa1\u306e\u305f\u3081\u306e\u79d1\u5b66\u7684\u60c5\u5831\u300d\u306e\u53d6\u308a\u307e\u3068\u3081\u3068\u4eca\u5f8c\u306e\u5c55\u671b\u3001\u5e73\u585a\u771f\u5f18\u3001\u5e73\u6fa4\u5178\u4fdd\u3001\u5927\u5cf6\u5409\u8f1d\u3001\u5150\u7389\u9032\u3001\u5bae\u7530\u654f\u7537\u3001\u6bb5\u5b5d\u3001\u9ad8\u5fb3\u656c\u4e4b\u3001\u6817\u6797\u79c0\u660e\u3001\u4e2d\u6751\u4eae\u4ecb\u3001\u658e\u85e4\u5609\u6717\u3001\u30ec\u30ae\u30e5\u30e9\u30c8\u30ea\u30fc\u30b5\u30a4\u30a8\u30f3\u30b9\u5b66\u4f1a\u8a8c\u30019:95-102 (2019)<\/li>\n\n\n\n
              5. Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.\u3000M. Hiratsuka, N. Hirasawa, Y. Oshima, S. Kodama, T. Miyata, T. Dan, H. Takatoku, H. Kuribayashi, R. Nakamura, Y. Saito.\u3000Drug Metab. Pharmacokinet., 33:141-149 (2018)<\/li>\n\n\n\n
              6. \u7279\u96c6\uff1a\u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c137\u5e74\u4f1a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u3001\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u3092\u76ee\u6307\u3057\u305f\u65e5\u672c\u4eba\u5168\u30b2\u30ce\u30e0\u30ea\u30d5\u30a1\u30ec\u30f3\u30b9\u30d1\u30cd\u30eb\u306b\u3088\u308b\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30c7\u30fc\u30bf\u89e3\u6790\u3001\u5e73\u585a\u771f\u5f18\u3001\u85ac\u5b66\u56f3\u66f8\u9928\u300162(4):206-210 (2017)<\/li>\n\n\n\n
              7. \u7279\u96c6\u30fb\u611f\u67d3\u75c7\u8a3a\u7642\u3092\u5909\u3048\u308b\u65b0\u3057\u3044\u8a3a\u65ad\u6280\u8853\u30fb\u691c\u67fb\u6cd5\u3001\u6838\u9178\u30af\u30ed\u30de\u30c8\u30b0\u30e9\u30d5\u30a3\u30fc\u6cd5\u3001\u5e73\u585a\u771f\u5f18\u3001\u9f4b\u85e4\u96c4\u5927\u3001\u5316\u5b66\u7642\u6cd5\u306e\u9818\u57df 33:87-95 (2017)<\/li>\n\n\n\n
              8. Genetic polymorphisms and in vitro functional characterization of CYP2C8, CYP2C9, and CYP2C19 allelic variants, Masahiro Hiratsuka, Biol. Pharm. Bull. 39:1748-1759 (2016)<\/li>\n\n\n\n
              9. \u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\uff08PGx\uff09\u60c5\u5831\u3092\u5229\u7528\u3057\u305f\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u306e\u5c55\u958b\u3001\u5e73\u585a\u771f\u5f18\u3001\u751f\u7269\u7269\u7406\u5316\u5b66 58:1-4 (2014)<\/li>\n\n\n\n
              10. \u7814\u7a76\u6226\u7565YAKU\u5b66-\u7814\u7a76\u73fe\u5834\u304b\u3089\u81e8\u5e8a\u3078-\u3001PGx\u60c5\u5831\u3092\u5229\u7528\u3057\u305f\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u306e\u5c55\u958b\u3001\u5e73\u585a\u771f\u5f18\u3001\u85ac\u4e8b\u65e5\u5831 \u7b2c11322\u53f7 8 (2013)<\/li>\n\n\n\n
              11. \u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u89e3\u6790\u306b\u3088\u308b\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u306e\u63a8\u9032\u3001\u5e73\u585a\u771f\u5f18\u3001\u533b\u7642\u85ac\u5b66 39(6): 327-337 (2013)<\/li>\n\n\n\n
              12. In vitro assessment of the allelic variants of cytochrome P450, Masahiro Hiratsuka, Drug Metab. Pharmacokinet. 27, 68-84 (2012)<\/li>\n\n\n\n
              13. \u81e8\u5e8a\u691c\u67fb\u30ab\u30ec\u30c3\u30b8\uff1a\u907a\u4f1d\u5b50\u691c\u67fb\u3001\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u3068\u907a\u4f1d\u5b50\u591a\u578b\u8a3a\u65ad\u3001\u5e73\u585a\u771f\u5f18\u3001\u533b\u7642\u3068\u691c\u67fb\u6a5f\u5668\u30fb\u8a66\u85ac\u300133:197-201 (2010)<\/li>\n\n\n\n
              14. \u907a\u4f1d\u5b50\u8a3a\u7642\u5b66\uff08\u7b2c2\u7248\uff09\uff0d\u907a\u4f1d\u5b50\u8a3a\u65ad\u306e\u9032\u6b69\u3068\u30b2\u30ce\u30e0\u6cbb\u7642\u306e\u5c55\u671b\u3001\u85ac\u5264\u611f\u53d7\u6027\u306b\u95a2\u3059\u308b\u907a\u4f1d\u5b50\u89e3\u6790\u3001\u5e73\u585a\u771f\u5f18\u3001\u5de5\u85e4\u7766\u3001\u4f5c\u5c71\u4f73\u5948\u5b50\u3001\u65e5\u672c\u81e8\u7240\u30016:269-274 (2010)<\/li>\n<\/ol>\n\n\n\n

                \u53d7\u8cde\uff08\u6559\u54e1\uff09<\/h4>\n\n\n\n
                  \n
                1. \u4ee4\u548c4\u5e74\u5ea6\u7814\u7a76\u79d1\u9577\u8cde\uff08\u5916\u90e8\u8cc7\u91d1\u306e\u76f4\u63a5\u7d4c\u8cbb\u3068\u9593\u63a5\u7d4c\u8cbb\u306e\u5408\u8a08\u7372\u5f97\u984d\u304c\u591a\u3044\u8005\uff09\u3092\u53d7\u8cde\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                2. \u4ee4\u548c3\u5e74\u5ea6\u7814\u7a76\u79d1\u9577\u8cde\uff08\u5916\u90e8\u8cc7\u91d1\u306e\u76f4\u63a5\u7d4c\u8cbb\u3068\u9593\u63a5\u7d4c\u8cbb\u306e\u5408\u8a08\u7372\u5f97\u984d\u304c\u591a\u3044\u8005\uff09\u3092\u53d7\u8cde\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                3. \u4ee4\u548c2\u5e74\u5ea6\u7814\u7a76\u79d1\u9577\u8cde\uff08\u5916\u90e8\u8cc7\u91d1\u306e\u76f4\u63a5\u7d4c\u8cbb\u3068\u9593\u63a5\u7d4c\u8cbb\u306e\u5408\u8a08\u7372\u5f97\u984d\u304c\u591a\u3044\u8005\uff09\u3092\u53d7\u8cde\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                4. \u6771\u4eac\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u30fb\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u6280\u8853\u7814\u7a76\u7d44\u5408\uff08TOBIRA\uff09\u306e\u7b2c6\u56deTOBIRA\u7814\u7a76\u52a9\u6210\u3068\u3073\u3089\u8cde\u304a\u3088\u3073\u5968\u52b1\u8cde\u3092\u53d7\u8cde\uff1a\u6838\u9178\u30af\u30ed\u30de\u30c8\u30b0\u30e9\u30d5\u30a3\u30fc\u3092\u5229\u7528\u3057\u305f\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u691c\u67fb\u85ac\u306e\u958b\u767a\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                5. \u672a\u6765\u578b\u533b\u7642\u62e0\u70b9\u30ad\u30c3\u30af\u30aa\u30d5 \u7b2c\u4e8c\u56de\u30ab\u30ed\u30ea\u30f3\u30b9\u30ab\u7814\u7a76\u6240\u30fb\u6771\u5317\u5927\u5b66\u5408\u540c\u4f1a\u8b70\u3067Young Investigator Award\u3092\u53d7\u8cde\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                6. \u5e73\u621029\u5e74\u5ea6\u7814\u7a76\u79d1\u9577\u8cde\uff08\u6559\u80b2\u6d3b\u52d5\u306b\u512a\u308c\u305f\u8ca2\u732e\u304c\u3042\u3063\u305f\u8005\uff09\u3092\u53d7\u8cde\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                7. \u5e73\u621028\u5e74\u5ea6\u65e5\u672c\u85ac\u5b66\u4f1a\u5b66\u8853\u632f\u8208\u8cde\u3092\u53d7\u8cde\uff1a\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u3092\u76ee\u6307\u3057\u305f\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u89e3\u6790\u306b\u95a2\u3059\u308b\u7814\u7a76\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                8. \u5e73\u621027\u5e74\u5ea6\u7814\u7a76\u79d1\u9577\u8cde\uff08\u7279\u306b\u512a\u308c\u305f\u7814\u7a76\u3092\u884c\u3063\u305f\u8005\uff09\u3092\u53d7\u8cde\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                9. \u5e73\u621026\u5e74\u5ea6\u7b2c24\u56de\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5e74\u4f1a \u512a\u79c0\u6f14\u984c\u8cde\u3092\u53d7\u8cde\uff1a\u30ab\u30da\u30b7\u30bf\u30d3\u30f3\u6295\u4e0e\u306b\u3088\u308a\u91cd\u7be4\u526f\u4f5c\u7528\u3092\u767a\u73fe\u3057\u305f\u60a3\u8005\u53ca\u3073\u305d\u306e\u5bb6\u65cf\u306e\u30b8\u30d2\u30c9\u30ed\u30d4\u30ea\u30df\u30b8\u30ca\u30fc\u30bc\u907a\u4f1d\u5b50\u591a\u578b\u3068\u5c3f\u4e2d\u30d4\u30ea\u30df\u30b8\u30f3\u89e3\u6790\uff08\u5e73\u585a\u771f\u5f18\u3001\u5c71\u4e0b\u6d0b\u3001\u8d64\u4e95\u6587\u9999\u3001\u7d30\u91ce\u5bdb\u8cb4\u3001\u5e73\u6fa4\u5178\u4fdd\u3001\u68ee\u9686\u5f18\uff09<\/li>\n\n\n\n
                10. \u5e73\u621026\u5e74\u5ea6\u7b2c7\u56de\u81e8\u5e8a\u85ac\u7406\u7814\u7a76\u632f\u8208\u8ca1\u56e3 \u7814\u7a76\u5927\u8cde\u3092\u53d7\u8cde\uff1a\u85ac\u7269\u4ee3\u8b1d\u306b\u304a\u3051\u308b\u500b\u4f53\u5dee\u306e\u4e88\u6e2c\uff1a\u30ef\u30eb\u30d5\u30a1\u30ea\u30f3\u3092\u7528\u3044\u305f32 \u7a2e\u306eCYP2C9 \u907a\u4f1d\u5b50\u591a\u578b\u30d0\u30ea\u30a2\u30f3\u30c8\u9175\u7d20\u306e\u6a5f\u80fd\u5909\u5316\u89e3\u6790\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                11. \u5e73\u621024\u5e74\u5ea6\u65e5\u672c\u533b\u7642\u85ac\u5b66\u4f1a\u5b66\u8853\u8ca2\u732e\u8cde\u3092\u53d7\u8cde\uff1a\u30d5\u30a1\u30fc\u30de\u30b3\u30b2\u30ce\u30df\u30af\u30b9\u89e3\u6790\u306b\u3088\u308b\u500b\u5225\u5316\u85ac\u7269\u7642\u6cd5\u306e\u63a8\u9032\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n\n\n\n
                12. \u5e73\u621022\u5e74\u5ea6\u65e5\u672c\u85ac\u7269\u52d5\u614b\u5b66\u4f1a\u5968\u52b1\u8cde\u3092\u53d7\u8cde\uff1a\u85ac\u7269\u4ee3\u8b1d\u9175\u7d20\u907a\u4f1d\u5b50\u306eSNP\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3068\u30d0\u30ea\u30a2\u30f3\u30c8\u9175\u7d20\u306e\u6a5f\u80fd\u5909\u5316\u89e3\u6790\u306b\u95a2\u3059\u308b\u7814\u7a76\uff08\u5e73\u585a\u771f\u5f18\uff09<\/li>\n<\/ol>\n\n\n\n

                  \u53d7\u8cde\uff08\u5b66\u751f\uff09<\/h4>\n\n\n\n
                    \n
                  1. \u7b2c46\u56de\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30fb\u6700\u512a\u79c0\u6f14\u984c\u8cde\u30dd\u30b9\u30bf\u30fc\u90e8\u9580\uff08\u5bfa\u5185\u5065\u4eba\u3001M2\uff09<\/li>\n\n\n\n
                  2. \u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c145\u5e74\u4f1a\u30fb\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\u53e3\u982d\u767a\u8868\u90e8\u9580\uff08\u53d7\u8cde\u738720.3\uff05\uff09\uff08\u897f\u539f\u7fd4\u5927\u3001B4\uff09<\/li>\n\n\n\n
                  3. \u7b2c45\u56de\u65e5\u672c\u81e8\u5e8a\u85ac\u7406\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30fb\u512a\u79c0\u6f14\u984c\u8cde\u53e3\u6f14\u90e8\u9580\uff08\u5c0f\u6e15\u958b\u3001B6\uff09<\/li>\n\n\n\n
                  4. \u4ee4\u548c2\u5e74\u5ea6\u3000\u7814\u7a76\u79d1\u9577\u8cde\u30fb\u7b54\u8f9e\u7dcf\u4ee3\uff08\u516c\u6587\u4ee3\u5c07\u5e0c\u3001D4\uff09<\/li>\n\n\n\n
                  5. \u65e5\u672c\u85ac\u7269\u52d5\u614b\u5b66\u4f1a\u7b2c35\u5e74\u4f1a\u30fb\u512a\u79c0\u53e3\u982d\u767a\u8868\u8cde\uff08\u516c\u6587\u4ee3\u5c07\u5e0c\u3001D4\uff09<\/li>\n\n\n\n
                  6. \u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c139\u5e74\u4f1a\u30fb\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\u30dd\u30b9\u30bf\u30fc\u767a\u8868\u90e8\u9580\uff08\u53d7\u8cde\u738712.1\uff05\uff09\uff08\u6210\u7530\u7476\u5b50\u3001B5\uff09<\/li>\n\n\n\n
                  7. \u65e5\u672c\u5b66\u8853\u632f\u8208\u4f1a\u7279\u5225\u7814\u7a76\u54e1DC2\u306b\u9762\u63a5\u514d\u9664\u3067\u63a1\u7528\u5185\u5b9a\uff08\u9f4b\u85e4\u96c4\u5927\u3001D2\uff09<\/li>\n\n\n\n
                  8. \u7b2c54\u56de\u65e5\u672c\u85ac\u5b66\u4f1a\u6771\u5317\u652f\u90e8\u5927\u4f1a\u30fb\u82e5\u624b\u7814\u7a76\u8005\u767a\u8868\u8cde\uff08\u83f1\u6cbc\u82f1\u53f2\u3001D2\uff09<\/li>\n\n\n\n
                  9. \u7b2c53\u56de\u65e5\u672c\u85ac\u5b66\u4f1a\u6771\u5317\u652f\u90e8\u5927\u4f1a\u30fb\u82e5\u624b\u7814\u7a76\u8005\u767a\u8868\u8cde\uff08\u8d64\u4e95\u6587\u9999\u3001B4\uff09<\/li>\n\n\n\n
                  10. \u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c134\u5e74\u4f1a\u30fb\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\u53e3\u982d\u767a\u8868\u90e8\u9580\uff08\u585a\u7530\u667a\u6674\u3001B6\uff09<\/li>\n\n\n\n
                  11. \u65e5\u672c\u85ac\u5b66\u4f1a\u7b2c133\u5e74\u4f1a\u30fb\u5b66\u751f\u512a\u79c0\u767a\u8868\u8cde\u53e3\u982d\u767a\u8868\u90e8\u9580\uff08\u9f4b\u85e4\u96c4\u5927\u3001B6\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                    \u7814\u7a76\u696d\u7e3e \u5b66\u8853\u8ad6\u6587 \u5b66\u4f1a\u767a\u8868 \u56fd\u969b\u5b66\u4f1a\u62db\u5f85\u8b1b\u6f14 \u56fd\u5185\u5b66\u4f1a\u62db\u5f85\u8b1b\u6f14\u30fb\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u56fd\u969b\u5b66\u4f1a\u53e3\u982d\u767a\u8868 \u56fd\u969b\u5b66\u4f1a\u30dd\u30b9\u30bf\u30fc\u767a\u8868 \u56fd\u5185\u5b66\u4f1a\u53e3\u982d\u767a\u8868 \u56fd\u5185\u5b66\u4f1a\u30dd\u30b9\u30bf\u30fc\u767a\u8868 … <\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-16","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/pages\/16","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/comments?post=16"}],"version-history":[{"count":19,"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/pages\/16\/revisions"}],"predecessor-version":[{"id":310,"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/pages\/16\/revisions\/310"}],"wp:attachment":[{"href":"https:\/\/www.pharm.tohoku.ac.jp\/~genome\/wp-json\/wp\/v2\/media?parent=16"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}